Patents by Inventor Chunpu Li

Chunpu Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10836743
    Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 17, 2020
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Jia Li, Jiang Wang, Mingbo Su, Shuni Wang, Yubo Zhou, Wei Zhu, Wei Xu, Chunpu Li, Hualiang Jiang, Kaixian Chen
  • Publication number: 20190210998
    Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 11, 2019
    Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Jia Li, Wei Zhu, Yubo Zhou, Jiang Wang, Mingbo Su, Shuni Wang, Wei Xu, Chunpu Li, Weijuan Kan, Hualiang Jiang, Kaixian Chen
  • Publication number: 20190135818
    Abstract: The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.
    Type: Application
    Filed: May 24, 2017
    Publication date: May 9, 2019
    Inventors: Hualiang JIANG, Hong LIU, Meiyu GENG, Mingyue ZHENG, Jing AI, Yulan WANG, Xiaowei WU, Shuangjie LI, Xia PENG, Chunpu LI, Kaixian CHEN, Bao WANG
  • Publication number: 20190100507
    Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.
    Type: Application
    Filed: March 16, 2017
    Publication date: April 4, 2019
    Inventors: Hong LIU, Jia LI, Jiang WANG, Mingbo SU, Shuni WANG, Yubo ZHOU, Wei ZHU, Wei XU, Chunpu LI, Hualiang JIANG, Kaixian CHEN
  • Patent number: 8896673
    Abstract: A method for displaying 3D image is provided in the present invention.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: November 25, 2014
    Assignees: Hisense Electric Co., Ltd., Hisense Hiview Tech Co., Ltd.
    Inventors: Weidong Liu, Weisong Gao, Chunpu Li, Junhui Shang, Yuzhen Dong, Yongping Miao
  • Publication number: 20120120206
    Abstract: A method for displaying 3D image is provided in the present invention.
    Type: Application
    Filed: February 22, 2010
    Publication date: May 17, 2012
    Applicants: Hisense Hiview Tech Co., Ltd., Hisense Electric Co., Ltd.
    Inventors: Weidong Liu, Weisong Gao, Chunpu Li, Junhui Shang, Yuzhen Dong, Yongping Miao